AI Engines For more Details: Perplexity Kagi Labs You
Chronic Stable Angina: Ranolazine is indicated for the treatment of chronic stable angina, which is chest pain or discomfort that occurs when the heart muscle doesn't get enough oxygen-rich blood. By inhibiting the late sodium current in cardiac cells, ranolazine helps to improve myocardial blood flow and decrease the frequency of angina episodes.
Reduced Frequency of Angina Episodes: One of the primary effects of ranolazine is to reduce the frequency of angina episodes in individuals with chronic stable angina. By optimizing myocardial oxygen utilization, ranolazine helps to prevent or alleviate chest pain and improve exercise tolerance.
Improvement in Exercise Capacity: Ranolazine may improve exercise tolerance in individuals with chronic stable angina by reducing the frequency and severity of angina episodes during physical activity. This can lead to enhanced physical function and quality of life.
Adjunctive Therapy: Ranolazine is often used as adjunctive therapy in combination with other anti-anginal medications, such as beta-blockers, calcium channel blockers, or nitrates, especially in patients who have not achieved adequate symptom relief with standard treatments alone.
No Effect on Heart Rate or Blood Pressure: Unlike some other anti-anginal medications, ranolazine typically does not affect heart rate or blood pressure significantly. This makes it a suitable option for patients with coexisting conditions such as hypertension or bradycardia.
Cardiovascular Safety: Ranolazine has been shown to have a neutral effect on cardiovascular outcomes such as heart attack (myocardial infarction) and cardiovascular death in patients with chronic stable angina. It does not increase the risk of arrhythmias or sudden cardiac death.
Side Effects: Common side effects of ranolazine may include dizziness, headache, constipation, nausea, and vomiting. It may also cause QT interval prolongation, a type of heart rhythm disturbance, particularly at higher doses or in patients with certain risk factors. Therefore, careful monitoring of the QT interval is recommended during ranolazine therapy.
Dosage and Administration: Ranolazine is usually taken orally, with or without food, as directed by a healthcare professional. The dosage may vary depending on the individual patient's medical condition, kidney function, and other factors. It is essential to follow the prescribed dosage and administration instructions carefully.
Contraindications: Ranolazine is contraindicated in patients with preexisting QT prolongation, severe liver impairment, and concurrent use of potent CYP3A inhibitors or inducers. It should not be used in patients with acute coronary syndrome or those at risk of developing QT prolongation.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.5 | 0.4 | 0.25 |
| Age-Related Macular Degeneration and Glaucoma | 0 | 0 | |
| Allergic Rhinitis (Hay Fever) | 1.5 | 1.5 | |
| Allergies | 1.4 | 0.8 | 0.75 |
| Allergy to milk products | 0.9 | 0.2 | 3.5 |
| Alopecia (Hair Loss) | 0 | 0 | |
| Alzheimer's disease | 1.4 | 1.9 | -0.36 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2 | 0.4 | 4 |
| Ankylosing spondylitis | 1.5 | 1.2 | 0.25 |
| Anorexia Nervosa | 0.5 | -0.5 | |
| Antiphospholipid syndrome (APS) | 1.1 | 1.1 | |
| Asthma | 0.1 | 0.4 | -3 |
| Atherosclerosis | 0 | 1.1 | 0 |
| Atrial fibrillation | 0.9 | 1.3 | -0.44 |
| Autism | 4.3 | 3.7 | 0.16 |
| Barrett esophagus cancer | 0.1 | -0.1 | |
| benign prostatic hyperplasia | 0.2 | 0.2 | |
| Bipolar Disorder | 0.6 | 0.5 | 0.2 |
| Brain Trauma | 0 | 0.4 | 0 |
| Carcinoma | 1.2 | 0.9 | 0.33 |
| Celiac Disease | 2.1 | 0.8 | 1.63 |
| Cerebral Palsy | 0.2 | 0.4 | -1 |
| Chronic Fatigue Syndrome | 1.5 | 3.5 | -1.33 |
| Chronic Kidney Disease | 1.4 | 0.5 | 1.8 |
| Chronic Lyme | 0.4 | -0.4 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.5 | -0.67 |
| Chronic Urticaria (Hives) | 0.9 | 1.6 | -0.78 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.1 | 6 |
| Colorectal Cancer | 2.3 | 0.1 | 22 |
| Constipation | 1.3 | 0 | 0 |
| Coronary artery disease | 0.9 | 0.4 | 1.25 |
| COVID-19 | 2.3 | 4 | -0.74 |
| Crohn's Disease | 3.7 | 2.2 | 0.68 |
| cystic fibrosis | 0.6 | 0.4 | 0.5 |
| deep vein thrombosis | 0.6 | 0.1 | 5 |
| Depression | 2.7 | 2.3 | 0.17 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 1 | 1.1 | -0.1 |
| Endometriosis | 1.5 | 0.5 | 2 |
| Epilepsy | 1.6 | 0.4 | 3 |
| Fibromyalgia | 0.2 | 2.1 | -9.5 |
| Functional constipation / chronic idiopathic constipation | 2.8 | 2.5 | 0.12 |
| gallstone disease (gsd) | 0.3 | 0 | 0 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.7 | 0.1 | 16 |
| Generalized anxiety disorder | 1.4 | 0.9 | 0.56 |
| giant cell arteritis | 0.1 | -0.1 | |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 0.4 | -0.4 | |
| Graves' disease | 0.4 | 0.1 | 3 |
| Halitosis | 0.4 | 0.1 | 3 |
| Hashimoto's thyroiditis | 0.4 | 0.4 | 0 |
| Hidradenitis Suppurativa | 0.1 | 0.1 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.2 | 0.4 | 2 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | |
| hyperglycemia | 0.2 | 0.4 | -1 |
| Hyperlipidemia (High Blood Fats) | 0 | 0 | 0 |
| hypertension (High Blood Pressure | 0.7 | 2.3 | -2.29 |
| Hypothyroidism | 0.4 | -0.4 | |
| Hypoxia | 0.4 | 0.4 | |
| IgA nephropathy (IgAN) | 2.2 | -2.2 | |
| Inflammatory Bowel Disease | 2.8 | 2.7 | 0.04 |
| Insomnia | 0.5 | 0.4 | 0.25 |
| Intelligence | 0.6 | 0.7 | -0.17 |
| Intracranial aneurysms | 0.4 | 0 | 0 |
| Irritable Bowel Syndrome | 1.7 | 1.2 | 0.42 |
| Liver Cirrhosis | 1.7 | 1.1 | 0.55 |
| Long COVID | 4.2 | 2 | 1.1 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.2 | 0.2 | |
| ME/CFS with IBS | 0.2 | 1.2 | -5 |
| ME/CFS without IBS | 1.2 | 0.4 | 2 |
| Metabolic Syndrome | 3.9 | 3.2 | 0.22 |
| Mood Disorders | 3.5 | 2.3 | 0.52 |
| multiple chemical sensitivity [MCS] | 0.1 | 0.1 | |
| Multiple Sclerosis | 0.3 | 2.5 | -7.33 |
| Multiple system atrophy (MSA) | 0.2 | 0.2 | |
| Neuropathy (all types) | 0.1 | 0.2 | -1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.2 | 1.3 | -0.08 |
| Obesity | 3.1 | 1.3 | 1.38 |
| obsessive-compulsive disorder | 2.8 | 2.8 | 0 |
| Osteoarthritis | 1.6 | 1.6 | |
| Osteoporosis | 0.7 | 0.4 | 0.75 |
| pancreatic cancer | 0.6 | 0.6 | |
| Parkinson's Disease | 1 | 1.7 | -0.7 |
| Polycystic ovary syndrome | 1.5 | 0.6 | 1.5 |
| Postural orthostatic tachycardia syndrome | 0.1 | 0.4 | -3 |
| Premenstrual dysphoric disorder | 0 | 0 | |
| primary biliary cholangitis | 0 | 0 | |
| Psoriasis | 1.6 | 1.5 | 0.07 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.8 | 2.3 | 0.22 |
| Rosacea | 0.2 | -0.2 | |
| Schizophrenia | 1.7 | 0.6 | 1.83 |
| scoliosis | 0.4 | 0.4 | |
| Sjögren syndrome | 1.5 | 0.4 | 2.75 |
| Sleep Apnea | 0.4 | 0.8 | -1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0.5 | |
| Stress / posttraumatic stress disorder | 0.9 | 0.9 | 0 |
| Systemic Lupus Erythematosus | 3.2 | 0.5 | 5.4 |
| Tic Disorder | 1.2 | 0.7 | 0.71 |
| Tourette syndrome | 0.4 | -0.4 | |
| Type 1 Diabetes | 2.7 | 1 | 1.7 |
| Type 2 Diabetes | 4.6 | 3.7 | 0.24 |
| Ulcerative colitis | 1.2 | 2.9 | -1.42 |
| Unhealthy Ageing | 3.4 | 0.9 | 2.78 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.